Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rebif® Clear all
Completed Phase 3 Interventional Results available

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RebiSmart™
Device
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 3, 2026, 2:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

NCT00735007
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif® New Formulation (RNF) using RebiSmartTM
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional

AVONEX® Combination Trial - "ACT"

NCT00112034
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Methotrexate, IV methylprednisolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif®, Copaxone®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

NCT00391352
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

NCT01064401
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Sep 3, 2026, 2:01 PM EDT
Withdrawn Phase 4 Interventional

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115
View directory record Official record
Conditions
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions
interferon beta 1a, methotrexate, methylprednisolone
Drug
Lead sponsor
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

NCT01119677
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Avonex
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT00605215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo, Avonex®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2009 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
Device · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 3, 2026, 2:01 PM EDT
Completed No phase listed Observational

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

NCT00463710
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex® monotherapy (6.0 MIU administered i.m. each week)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Sep 3, 2026, 2:01 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

NCT00930553
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 3, 2026, 2:01 PM EDT
Completed No phase listed Observational

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Rebif, Tecfidera
Drug
Lead sponsor
IMS HEALTH GmbH & Co. OHG
Industry
Eligibility
18 Years to 55 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

NCT01500408
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 3, 2026, 2:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS

NCT04032171
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 3, 2026, 2:01 PM EDT
Completed No phase listed Observational

Therapy Optimization in Multiple Sclerosis (MS)

NCT00819000
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 3, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 3, 2026, 2:01 PM EDT